Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

@article{Eagling1997DifferentialIO,
  title={Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.},
  author={V. Eagling and D. Back and M. Barry},
  journal={British journal of clinical pharmacology},
  year={1997},
  volume={44 2},
  pages={
          190-4
        }
}
AIMS To compare the inhibitory potential of the HIV protease inhibitors saquinavir, ritonavir and indinavir against CYP1A2, CYP2C9, CYP2E1 and CYP3A4 catalysed metabolic reactions in human liver microsomes in vitro. METHODS Microsomes from six human livers were utilized in this study. The probe substrates were phenacetin (CYP1A2), tolbutamide (CYP2C9), chlorzoxazone (CYP2E1) and testosterone (CYP3A4). Metabolites were analysed by high performance liquid chromatography. IC50 (concentration of… Expand
328 Citations
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
  • 92
Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors
  • 220
Mechanism-Based Inactivation of CYP 3 A by HIV Protease Inhibitors
  • 11
  • PDF
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro
  • 66
Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir
  • 150
  • PDF
CONVERSION OF THE HIV PROTEASE INHIBITOR NELFINAVIR TO A BIOACTIVE METABOLITE BY HUMAN LIVER CYP2C19
  • 58
  • PDF
Apparent mechanism‐based inhibition of human CYP3A in‐vitro by lopinavir
  • 26
Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir
  • 255
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.
  • 328
Risks and synergies from drug interactions.
  • 36
Dexamethasone metabolism by human liver in vitro . pharmacokinetics alone and in combination with ritonavir in HIV infected patients
  • AIDS
  • 1997
Advances in antiretroviral therapy and viral load Mo . B . 1198 ) . monitoring
  • AIDS
  • 1996
HIV - 1 protease mediated toxicity by reducing the formation of the toxic inhibitors . A review for clinicians
  • Also , coadministration of ritonavir with Drug Metab Dispos
  • 1996
Pharmacokinetics of ritonavirsaquinavir combination therapy . of ethinyl estradiol in healthy volunteers . XI International Congress on AIDS Vancouver , July 1996 ( abstract No
  • Science
  • 1996
Protease inhibitors in AUC ) and desipramine ( 2 . 5 fold increase in AUC ) [ 9 , in patients with HIV disease : clinically important pharmacokinetic considerations
  • AIDS
  • 1996
The e ff ect of high dose saquinavir on viral load and CD 4 + T cell countsHowever , previous work has shown ritonavir to be inhibitory in HIV - infected patients
  • N Engl J Med
  • 1996
predicted interaction with ketoconazole
  • J Pharmacol Exp Ther
  • 1996
...
1
2
3
...